Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

164
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
164
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

160
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
160

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Study of electroreflectance spectrum and Franz-Keldysh effect at metal-GaAs interfaces].

Guang pu xue yu guang pu fen xi = Guang pu·2008
Same author

[Study on electro-degradation of new conjugated polymer PFO-BT15 light emitting diodes].

Guang pu xue yu guang pu fen xi = Guang pu·2008
Same author

Comparison of the curative effects of video assisted thoracoscopic anterior correction and small incision, thoracotomic anterior correction for idiopathic thoracic scoliosis.

Chinese medical journal·2008
Same author

Distribution and sources of mercury in soils from former industrialized urban areas of Beijing, China.

Environmental monitoring and assessment·2008
Same author

[Main flavonoids from Sophora flavescenes].

Yao xue xue bao = Acta pharmaceutica Sinica·2008
Same author

External validation and prediction employing the predictive squared correlation coefficient test set activity mean vs training set activity mean.

Journal of chemical information and modeling·2008

Related Experiment Video

Updated: May 5, 2026

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
11:52

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

11.0K

RGD-based self-assembling nanodrugs for improved tumor therapy.

Bin Wang1, Dongmei Tang2, Jianqiao Cui2

  • 1Department of Sports Medicine, Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.

Frontiers in Pharmacology
|October 16, 2024
PubMed
Summary

RGD-based nanodrugs show promise for targeted cancer therapy by improving drug delivery and reducing side effects. Further research is needed to overcome challenges for clinical use.

Keywords:
RGD peptidescancer therapyintegrin receptorsself-assembling nanodrugstumor targeting

More Related Videos

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies
08:54

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies

Published on: February 17, 2023

997
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

2.4K

Related Experiment Videos

Last Updated: May 5, 2026

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
11:52

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

11.0K
Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies
08:54

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies

Published on: February 17, 2023

997
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

2.4K

Area of Science:

  • Nanotechnology
  • Oncology
  • Biomedical Engineering

Background:

  • Targeted cancer therapy aims to improve treatment efficacy and reduce systemic toxicity.
  • Nanotechnology offers novel platforms for drug delivery, enhancing therapeutic outcomes.
  • RGD peptides are ligands that target integrins, often overexpressed on tumor cells.

Purpose of the Study:

  • To explore the potential of RGD-based self-assembling nanodrugs for enhanced cancer therapy.
  • To review the advantages and challenges associated with RGD-based nanodrug development.
  • To outline future research directions for clinical translation.

Main Methods:

  • Self-assembly of nanostructures using RGD peptides.
  • Nanoparticle characterization for stability and drug loading.
  • In vitro and in vivo studies for tumor targeting and cellular uptake evaluation.
  • Assessment of therapeutic efficacy and safety profiles.

Main Results:

  • RGD-based nanodrugs demonstrated enhanced tumor targeting and cellular uptake.
  • Self-assembling nanostructures facilitated efficient and stable drug delivery.
  • Reduced off-target effects were observed compared to conventional therapies.
  • Key challenges identified include immunogenicity, stability, tumor heterogeneity, and manufacturing scalability.

Conclusions:

  • RGD-based self-assembling nanodrugs represent a significant advancement in targeted cancer treatment.
  • Addressing challenges in biocompatibility, targeting, and manufacturing is crucial for clinical success.
  • Future research focusing on personalized medicine and innovative techniques will accelerate translation.
  • These nanodrugs hold the potential for more effective and safer cancer therapies.